University of Basrah
  • Register
  • Login
  • العربیة

The Medical Journal of Basrah University

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 37, Issue 1
  3. Author

Current Issue

By Issue

By Subject

Keyword Index

Author Index

Indexing Databases XML

About Journal

Aims and Scope

Editorial Board

Advisory Board

Editorial Staff

Facts and Figures

Publication Ethics

Indexing and Abstracting

Related Links

Peer Review Process

News

Cisplatin & IV Etoposide combination in the treatment of advanced breast cancer pretreated with anthracyclines

    Anmar A Allami

The Medical Journal of Basrah University, 2019, Volume 37, Issue 1, Pages 29-36
10.33762/mjbu.2019.163352

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Aims of this study was to determine the benefit of cisplatin and i.v etoposide combination in treatment of advanced breast cancer (ABC) patients who were pretreated with anthracyclines, as an alternative to the newer, more expensive, and unavailable anticancer drugs like Taxanes, carboplatin, and gemcitabine.Patients and methods: The study was performed in the period from March 2010 to June 2016, 235 patients were given cisplatin 50mg/m2 and etoposide 100mg /m2 for 6 cycles. The patients were divided into 4 groups according to the site of metastasis (vertebral metastases, liver metastases, loco-regional metastases, and pleuro-pulmonary metastases).Results: Evaluation of treatment was considered on two levels: Whole 235 patient level, and patient-group level. On whole patient level: Response to Treatment was 65.1%, which is higher than similar responses in many other studies. While on patient-group level: response to treatment was highest in patients with vertebral secondaries 75.3%. There was drug toxicity in all groups of patients. Some patients did not continue the treatment protocol because of bad performance status, toxicity and death. Conclusion: In comparison with other regimes of chemotherapy cisplatin and i.v etoposide are still useful anticancer drugs in the management of advanced breast cancer.
Keywords:
    advanced breast cancerو anthracyclinesو taxanesو cisplatinو etoposide
Main Subjects:
  • Medicine
  • PDF (640 K)
  • XML
(2019). Cisplatin & IV Etoposide combination in the treatment of advanced breast cancer pretreated with anthracyclines. The Medical Journal of Basrah University, 37(1), 29-36. doi: 10.33762/mjbu.2019.163352
Anmar A Allami. "Cisplatin & IV Etoposide combination in the treatment of advanced breast cancer pretreated with anthracyclines". The Medical Journal of Basrah University, 37, 1, 2019, 29-36. doi: 10.33762/mjbu.2019.163352
(2019). 'Cisplatin & IV Etoposide combination in the treatment of advanced breast cancer pretreated with anthracyclines', The Medical Journal of Basrah University, 37(1), pp. 29-36. doi: 10.33762/mjbu.2019.163352
Cisplatin & IV Etoposide combination in the treatment of advanced breast cancer pretreated with anthracyclines. The Medical Journal of Basrah University, 2019; 37(1): 29-36. doi: 10.33762/mjbu.2019.163352
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 183
  • PDF Download: 174
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

 
This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus